In order to achieve targeted delivery of antigens and/or adjuvants, nanoparticles are decorated with diverse targeting ligands or Abs on the surface.171 As a DC‐targeting tumor vaccine in phase I trial stage (NCT01052142), Lipovaxin MM contains melanoma cell‐derived antigens, human IFN‐γ, and an Ab fragment targeting DC‐specific intercellular adhesion molecule‐3‐grabbing nonintegrin. The gene discussed is IFNG; the disease is neoplasm.